Wednesday, July 8, 2026

pharma · Influenza · Celiac Disease · BRNS

Barinthus Biotherapeutics

Barinthus Biotherapeutics is a pharma organization headquartered in Harwell, GB. It trades on NYSE under ticker BRNS. Primary therapeutic focus areas include Influenza, Celiac Disease, Chronic Hepatitis B, Hepatitis B, H

Harwell, GB HQ
2016 Founded
36 Employees
Public company Type
BRNS · NYSE Ticker
Company details
Status
Public
HQ
Harwell, GB
Founded
2016
Employees
36
Programs
9
Drugs
5
Patents
0
Clinical program

Seasonal influenza vaccine

Phase 2 · small molecule · Influenza

Seasonal influenza vaccine for Influenza is a Phase 2 program (small_molecule) at Barinthus Biotherapeutics plc. with 1 ClinicalTrials.gov record(s).

← All Barinthus Biotherapeutics plc. projects Phase 2 small molecule terminated

Internal code FLU007 INVICTUS

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Barinthus Biotherapeutics plc.
Phase
Phase 2
Modality
small_molecule
Indication
Influenza
Status
terminated
Trials
1